Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xenon Pharmaceuticals Inc XENE

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the... see more

Recent & Breaking News (NDAQ:XENE)

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire November 13, 2020

Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire November 5, 2020

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update

GlobeNewswire November 2, 2020

Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE Before Year-End

GlobeNewswire October 8, 2020

Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy

GlobeNewswire October 8, 2020

Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer

GlobeNewswire August 17, 2020

Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire August 6, 2020

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire August 4, 2020

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update

GlobeNewswire July 30, 2020

Xenon Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference

GlobeNewswire June 1, 2020

Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire May 21, 2020

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Provide Corporate Update

GlobeNewswire May 14, 2020

Xenon Pharmaceuticals Provides Corporate Update in the Context of COVID-19

GlobeNewswire March 31, 2020

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 26, 2020

Xenon Pharmaceuticals Reports 2019 Financial Results and Provides Corporate Update

GlobeNewswire March 9, 2020

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2019 Financial Results and Provide Corporate Update

GlobeNewswire March 2, 2020

Xenon Pharmaceuticals Announces Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 14, 2020

Xenon Pharmaceuticals Announces Closing of its $60.0 Million Public Offering of Common Shares

GlobeNewswire January 27, 2020

Xenon Pharmaceuticals Announces Pricing of $60.0 Million Public Offering of Common Shares

GlobeNewswire January 22, 2020

Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares

GlobeNewswire January 22, 2020